1
Background 21
Gastric cancer (GC) is a highly morbid and prevalent global disease and is the second leading 22 cause of cancer related deaths worldwide in 2018 1 . Such a dismal prognosis is a result of advanced 23 stage at diagnosis coupled with demonstrated resistance to chemotherapy 2 and few available 1 targeted options 3 . Docetaxel has been FDA approved as a first line therapy for GC when combined 2 with Cisplatin and 5-Fluorouracil 4 , and paclitaxel is a standard second line treatment option 5 . 3
Notably, a large proportion of patients demonstrate resistance to taxane treatment, with response 4 rates to single agent therapy around 14-25%, and duration of response measured in months 6,7 . This 5 is further recapitulated in our post-hoc analysis of the trial that led to the approval of docetaxel as 6 first line treatment in GC 8 , in which we identified a significant subset of GC patients who did not 7 derive any clinical benefit from docetaxel chemotherapy. Thus, there is a dire need to decipher 8 clinically actionable mechanisms of taxane resistance. 9
Despite the multitude of taxane resistance mechanisms described in preclinical models by 10 us and others, including tubulin mutations, altered MT dynamics or the presence of drug efflux 11 mechanisms, none has impacted clinical care [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . 12
Here we describe a novel truncated variant of the MT plus-end binding protein CLIP170, 13 hereafter CLIP170S, which we found to be significantly enriched in taxane-resistant GC cell lines 14 and patient samples. CLIP-170 binds to the plus-end of growing MTs and is involved in the 15 regulation of MT dynamics, positioning of MT arrays and signaling 20 . We demonstrate a direct 16 role for CLIP-170S in conferring taxane resistance in gastric cancer by obstruction of the MT pore, 17 thereby preventing taxane internalization into the MT lumen. Using a systems biology approach, 18 we discovered the tyrosine kinase inhibitor, imatinib, as a compound predicted to reverse taxane 19 resistance. Mechanistically we show that imatinib sensitizes resistant GC cell lines to taxane 20 therapy by selective depletion of CLIP-170S. Taken together, this study describes a novel +TIP 21 protein variant with distinct biological properties, a previously unrecognized mechanism of taxane 22 resistance that involves obstruction of the MT pore, and identifies an actionable therapeutic 1 strategy to treat patients with taxane refractory GC. 2 3 Results 4
Taxane-resistant GC cells exhibit reduced Flutax-2 residence time on microtubules 5
We have previously reported that taxane resistance in gastric cancer (GC) is associated with 6 reduced drug target engagement in both cell lines and patient biopsies 8 . Using a panel of 12 GC 7 cell lines, we identified a subset (6/12) with intrinsic resistance to DTX which was due to lack of 8 drug-target engagement, despite unimpaired intracellular drug accumulation and absence of 9 tubulin mutations or other target alterations. To understand the molecular basis of the impaired 10 interaction between taxanes and MTs we incubated native cytoskeletons from sensitive and 11 resistant GC cells with FITC-conjugated paclitaxel (Flutax-2) and determined its binding 12 equilibrium with MTs by live cell imaging, as previously described 21 ( Figure 1A ). As can be seen, 13
initially Flutax-2 bound to both sensitive and resistant cell cytoskeletons ( Figure 1B , 14 Supplementary figure 1A) and was allowed to equilibrate following wash out. Flutax-2 remained 15 bound to native cytoskeletons from the TMK1 taxane-sensitive cell line for the duration of the 16 experiment (180 min) ( Figure 1B ). In the case of the resistant Hs746T and SCH cells, the drug had 17 to dissociate significantly in order to reach the binding equilibrium, thus, suggesting a higher 18 dissociation constant for the resistant cell cytoskeletons ( Figure 1B and Supplementary Figure  19 1A). 20
The equilibrium of Flutax-2 binding is a function of its association rate constant (kon), a 21 bimolecular reaction that depends on the diffusion constant of the drug, and dissociation rate 22 constant (koff), a monomolecular reaction. Thus, an altered kon in the absence of an altered koff would 23 imply altered diffusion of the drug to the luminal site of MTs, while an altered koff alone would 1 imply that the binding site itself is altered. 2 Quantitation of Flutax-2 association and dissociation rate constants revealed a 3-fold lower 3 kon value in resistant Hs746T (2 ± 1 x 10 4 M -1 s -1 ) versus sensitive TMK1 (6 ± 2 x 10 4 M -1 s -1 ) cells 4 (Supplementary figure 2A) . In contrast, no major differences were observed in their respective koff 5 dvalues (Hs746T: 4.3 ± 0.5x10 -2 s -1 vs TMK1: 3.5 ± 0.4 x 10 -2 s -1 ) (Supplementary figure 2B) . 6
Taken together, these data demonstrate that the lower equilibrium binding constant of 7 taxanes for resistant cell cytoskeletons arises from the slower association rate constant (kon) 8
indicating an impaired diffusion of the drug to the luminal binding site in MTs 22 . Our proposed 9 mechanism suggests a paradigm-shift in our understanding of taxane resistance, wherein impaired 10 drug access to the binding site, as opposed to site structural alterations, affects target engagement. 11 12
Identification of a novel N-terminal truncated variant of plus-end binding protein CLIP-170 13
In characterizing sensitive and resistant GC cell lines, we observed altered microtubule dynamics 14 at baseline, quantified by live cell imaging of MT plus ends labeled by EB1-GFP. We found that 15 resistant cells displayed significantly lower rates of MT growth speed and rescue/repolymerization 16 as compared to the sensitive GC cell lines 8 , suggesting that MT dynamics and the proteins 17 regulating them may underlie taxane resistance in these cells. We focused particularly on one such 18 MT +TIP protein, the CAP-Gly domain containing linker protein, CLIP-170, expression of which 19 has been shown to have an inverse correlation with taxane resistance in breast cancer cell lines 23 . 20 CLIP-170 was the first identified +TIP protein that binds to MT plus-ends via its association with 21
End-binding protein-1 (EB1) and links MTs to endoplasmic vesicles in addition to regulating MT 22 dynamics 24-28 (reviewed in 20,29 ). 23
Interrogation of GC sensitive and resistant lines for CLIP-170 protein expression revealed 1 the presence of a novel faster migrating isoform of CLIP-170, hereafter CLIP-170S, in addition to 2 the canonical full-length protein (Figure 2A ). Notably, this result was obtained when we used an 3 anti-C-terminal CLIP-170 antibody, while anti-N-terminal antibody detected only the canonical 4 protein, suggesting an N-terminal truncation in CLIP-170S. Interestingly, CLIP-170S was 5 preferentially expressed in taxane-resistant GC cell lines (Figure 2A ). Expanding this analysis to 6 the entire panel of 12 GC cell lines revealed that CLIP-170S was significantly enriched in taxane-7 resistant cell lines with 4/6 resistant versus only 1/6 sensitive cell lines expressing CLIP-170S (p< 8 0.05) ( Figure 2B ). We next performed immunoprecipitation followed by mass spectrometry and 9 showed that CLIP-170S lacks the first 150 amino acids from its N-terminus compared to the 10 canonical full-length protein ( Figure 2C ), confirming the size and identity of the faster migrating 11 protein in 2A. Consistent with these results, 5'-rapid amplification of cDNA ends (5'-RACE) 12 identified two CLIP-170 transcripts in the Hs746T and SCH resistant cells expressing both 13 variants. The first transcript corresponded to the canonical CLIP-170 while the second, less 14 abundant transcript, had a start site in exon 3, in the resistant but not in the sensitive GC lines 15 (Supplementary figure 3). These transcripts that start in exon 3 would utilize the putative start 16 codon at position 620 (amino acid position 155) and therefore, generate a protein of about 140kDa 17 in agreement with the results in 2A. Based on these results we generated a predicted exon structure 18 for CLIP-170S with the putative translation start site and the known protein domains of CLIP-170 19 displayed ( Figure 2D ). Taken together, we have identified CLIP-170S as a novel, shorter protein 20 variant of CLIP-170, expression of which is preferentially enriched in taxane resistant GC cell 21
lines. 22

CLIP-170S is mislocalized from the microtubule plus-ends to the lattice 1
The N-terminus of CLIP-170 contains two cytoskeleton-associated protein glycine-rich (CAP-2 Gly) domains that mediate MT binding and plus-end tracking via binding to End-binding protein-3 1 (EB1) 24, 25 . Of the two domains the first Cap-Gly binds stronger to EB1, an interaction that is 4 required for plus end tracking, while the second Cap-Gly motif demonstrates higher affinity for 5
MTs 30-32 . 6
The predicted exon structure for CLIP-170S indicates loss of the first Cap-Gly motif, 7 suggesting potential defects with plus-end tracking. Immunofluorescence staining of endogenous 8 Additionally, separation of endogenous MT polymers from soluble tubulin dimers by 16 centrifugation in Hs746T cells followed by immunoblot, showed that CLIP-170S preferentially 17 associated with the MT polymers present in the pellet fraction in contrast to CLIP-170 which was 18 predominantly found in the soluble fraction ( Figure 3C ). Taken together, these data provide 19 evidence for distinct cellular localization of CLIP-170S, preferentially associated with the MT 20 polymers along the lattice and defective plus-end MT tracking. 21
22
CLIP-170S depletion reverses taxane resistance in GC cells 23
To determine causation, we stably knocked-down CLIP-170 and CLIP-170S from sensitive and 1 resistant GC cell lines and performed cytotoxicity experiments. Stable knock-down (KD) of both 2 CLIP-170 and CLIP-170S completely reversed taxane resistance (~300-fold) in Hs 746T cells, 3 whereas knockdown of canonical CLIP-170 only in sensitive TMK1 cells had no effect on taxane 4 sensitivity ( Figure 3D ). We found no difference in the cellular growth rates in cells expressing 5 scramble or the CLIP-specific shRNA ( Figure 3D inset), ruling out faster growth rates as a 6 contributing factor to enhanced taxane sensitivity. 7
To determine the effect of CLIP-170S depletion on MT residence time of Flutax-2, we 8 treated native cytoskeletons from Hs746T cells stably expressing scrambled or CLIP-170 shRNA 9
with Flutax-2 and quantified drug binding over time. Similar to the results shown in Figure 1C , 10 we observed significant reduction in Flutax-2 binding to native cytoskeletons in control Hs746T-11
Scrambled shRNA cells (0 min vs 45 mins, p < 0.0001). In contrast, in Hs746T-CLIP-170-KD 12 cells, Flutax-2 binding equilibrium remained unchanged for the duration of the experiment 13 suggesting that CLIP-170 depletion restores Flutax-2 binding to MTs (Supplementary Figure 5) . 14 CLIP-170-KD in TMK1 cells expressing only the canonical protein did not have any effect of 15 Flutax-2 binding equilibrium (data not shown). Taken together, these results demonstrate causation 16 between CLIP-170S expression and altered taxane binding efficiency. 17
18
CLIP-170S confers taxane resistance via obstruction of the MT pore 19
To elucidate the mechanism underlying CLIP-170S mediated taxane resistance we focused our 20 investigation on taxane binding to the outer and inner MT surface as CLIP-170S exhibited 21 extensive and aberrant localization to the MT lattice. Taxane binding is a two-step process 33 . The 22
first step involves initial low affinity binding to the outer wall of MTs near pore type I sites, which 23 then allows translocation of the drug to its high affinity, but kinetically unfavorable, luminal 1 binding site (Supplementary Figure 6A ). 2
Using different chemical probes that interact with the outer versus inner MT surface, we 3 treated native cytoskeletons from sensitive and resistant cells expressing canonical only versus 4 both CLIP-170 variants. Treatment with hexaflutax, a fluorescently labelled taxoid known to bind 5 to the outer-only site of the MT pore 34 , revealed significantly reduced drug binding to native 6 cytoskeletons from resistant versus sensitive cell lines (p < 0.0001) ( Figure 4A ). 7
On the other hand, cyclostreptin is known to bind covalently to both the MT pores and 8 luminal taxoid binding site 33,35 and strongly inhibits taxane binding. We quantified Flutax-2 9 binding in cyclostreptin pre-treated native cytoskeleton from sensitive and resistant GC cell lines 10 ( Figure 4B ). We observed significant reduction in Flutax-2 binding proportional to the duration of 11 cyclostreptin pre-treatment in sensitive TMK1 (0 vs 2 min; p < 0.0001) but not in the resistant 12
Hs746T cells ( Figure 4C ). In addition, CLIP-170-KD had no effect in TMK1 cells following KD 13 of full-length only, while it significantly reduced Flutax-2 binding in cyclostreptin pre-treated 14
Hs746T cells following KD of both canonical and short variant ( Supplementary Figure 7) . 15
Together these results suggested that CLIP-170S in Hs746T cells likely obstructs the MT pore, 16 thus kinetically impairing cyclostreptin's irreversible binding to the site and therefore preventing 17 it from abolishing Flutax-2 binding. 18
To further probe the involvement of the MT pore, we used peloruside, a compound that 19 binds to a distinct non-taxoid pocket on tubulin 36,37 and does not interact with the MT pore 38 . We 20 found that peloruside was equally effective in both taxane sensitive and resistant GC cells, 21
including the isogenic Hs746T cells stably expressing CLIP-170 or scrambled shRNA 22
( Supplementary Figure 8 ). Taken together these data strongly support a mechanism whereby 23 CLIP-170S obstructs the MT pore and impairs effective drug target engagement (working model, 1
Supplementary Figure 6B ). 2 3 Computational analysis predicts Imatinib as a top candidate to reverse taxane resistance in 4 GC by selective depletion of CLIP-170S 5
We have previously described how different data types can be combined in a single computational 6 framework to identify protein targets for small molecules in development and to predict new 7 molecules to overcome drug resistance 39 . Here we used gene expression signatures, derived 8
following RNAseq expression analysis of untreated vs DTX-treated sensitive and resistant cell 9 lines, and generated a DTX-resistance signature for our panel of GC cell lines. We then evaluated 10 a set of FDA-approved drugs and active compounds and ranked them based on their potential to 11 reverse this DTX-resistance signature. This analysis identified imatinib as the top hit compound 12 predicted to reverse this taxane resistance in GC cells ( Figure 5A ). Imatinib is a BCR-Abl inhibitor 13 FDA approved for the treatment of chronic myelogenous leukemia 40,41 without any mechanistic 14 implications in MT biology or taxane activity. While treatment with imatinib alone did not show 15 differential activity in sensitive versus resistant cells, when combined with DTX it completely 16 reversed taxane resistance in Hs746T and other resistant cell lines ( Figure 5B and data not shown) 17 strongly indicating a mechanistic interaction between the two drugs. Intriguingly, we demonstrate 18 that a mere 3 hr treatment with imatinib lead to selective and profound inhibition of CLIP-170S in 19
Hs746T without affecting canonical CLIP-170 in neither resistant nor sensitive GC cells ( Figure  20 5C). Importantly, the imatinib concentration that depletes CLIP-170S and restores taxane 21 sensitivity, is a physiologically achievable concentration in patients 42 . 22
To further determine if Imatinib-mediated reversal of taxane resistance was specific to 23 CLIP-170S inhibition we performed a cytotoxicity experiment in Hs746T-CLIP-170-KD. Imatinib 1 did not further sensitize these cells to DTX, confirming the central role of CLIP-170S in this 2 synergistic interaction ( Figure 5D ). These data were corroborated by combination index analysis 3 to assess the extent of synergy between the two drugs, which showed synergistic interaction in the 4
Hs746T cells (CI ~0.5) but lack thereof upon CLIP-170 depletion (CI> 1.2) (Supplementary Figure  5   9 ). 6 7
CLIP-170S expression is highly prevalent in tumor biopsies from GC patients 8
To investigate the clinical relevance of CLIP-170S expression, we assessed CLIP-170S expression 9 in a cohort of GC patients. We identified the presence of CLIP-170S in 25/37 tumor samples, 10 giving a prevalence of CLIP-170S of 67.5% (95% CI 52.2 -82.8 %) (data not shown). Using a panel of GC cell lines and patient tumors we show, for the first time, that CLIP-2 170S mislocalization to the MT lattice results in taxane resistance by occlusion of the MT pore 3 which limits taxane access to its high affinity binding site in the MT lumen (Figure 3 and 4) . To 4 the best of our knowledge the MT pore has not been previously implicated in taxane resistance in 5 vitro, which together with the high prevalence of CLIP-170S in gastric tumors, provides a 6 paradigm shift in our understanding of clinical taxane resistance. 7
The discovery of the MT pore type I as an external, transient interaction site for taxanes 8 on the outer MT wall helped explain how taxanes reach the kinetically unfavorable luminal binding 9 site 33,34,46 and reviewed in 47 . Nevertheless, there has been paucity of data regarding biological 10 roles for the MT pore beyond facilitating taxane internalization to the MT lumen 22 . Our work 11 provides new insights where obstruction of the MT pore alone diminishes taxane activity, 12 consistent with absence of tubulin structural alterations in our model, thus representing a never-13 before described mechanism of resistance. 14 Having identified the integrity of the MT pore as an actionable therapeutic target, we 15 employed systems biology and discovered that Imatinib (Gleevec) reverses taxane resistance in 16 CLIP-170S expressing GC by restoring the MT pore integrity following selective depletion of 17 CLIP-170S. This was an unexpected finding as Imatinib primarily targets BCR-ABL fusion 18 protein in chronic mylogenous leukemia (CML) 40,41,48,49 as well as other receptor tyrosine kinases 19 (RTKs) including PDGFR, VEGFR, c-Abl and c-kit 50,51 , none of which was expressed in our GC 20 cell line panel (data not shown). We envision that this work will pave the way for unprecedented 21 clinical benefits for taxane-refractory patients expressing CLIP-170S or potentially other MT-pore 22 occluding proteins. 23 Hs746T and TMK1 cells were treated with 1, 25, 50 and 100 µM Imatinib for 3 hr and processed for immunoblotting using antibodies against the C-terminus of CLIP-170 or tubulin. D) Imatinib has no effect on Hs746T-CLIP-170-KD sensitivity to docetaxel. Cytotoxicity assay as in B.
